Skip to main content

Advertisement

SpringerLink
Log in

Plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in diabetic foot ulcers

  • Original Article
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Plasma TAFI may participate in arterial thrombosis in cardiovascular diseases (CVD) and may be involved in the mechanism of vascular endothelial damage in diabetic patients. The aim of this study was to investigate the association of plasma TAFI antigen level in the development of diabetic foot ulcer in Type 2 diabetes. The TAFI antigen levels were determined in 50 patients with diabetic foot ulcers and 34 patients without diabetic foot ulcers and 25 healthy individuals. We measured TAFIa/ai antigen in plasma samples with a commercially available ELISA Kit. Diabetic foot ulcer group and diabetic group were similar in terms of mean age and sex distribution. Diabetes duration, retinopathy, neuropathy, macrovascular disease and infection were related to diabetic foot ulcers. HbA1c, HDL-cholesterol and Folic Acid levels were decreased in the diabetic foot ulcer group. TAFI levels were 99.44 ± 55.94% in control group, 135.21 ± 61.05% in diabetic foot ulcer group, 136.75 ± 59.38% in diabetic group and was statistically different (P < 0.05). But no difference was seen in TAFI levels between the diabetic foot ulcer group and diabetic group (P > 0.05). No significant difference in plasma TAFI levels were seen between diabetic foot ulcer stages. TAFI antigen levels are increased in Type 2 diabetic patients, but are not related to diabetic foot ulcer development.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. J.L. Richard, S. Schuldiner, Epidemiology of diabetic foot problems. Rev. Med. Interne 29(Suppl 2), S222–S230 (2008)

    Article  PubMed  Google Scholar 

  2. D. Malgrange, Physiopathology of the diabetic foot. Rev. Med. Interne 29(Suppl 2), S231–S237 (2008)

    Article  PubMed  Google Scholar 

  3. C. Figueroa-Romero, M. Sadidi, E.L. Feldman, Mechanisms of disease: the oxidative stress theory of diabetic neuropathy. Rev. Endocr. Metab. Disord. 9(4), 301–314 (2008)

    Article  CAS  PubMed  Google Scholar 

  4. J. Martini, Diabetic foot: detection and prevention. Rev. Med. Interne 29(Suppl 2), S260–S263 (2008)

    Article  PubMed  Google Scholar 

  5. I. Got, Peripheral vascular disease and diabetic foot. Rev. Med. Interne 29(Suppl 2), S249–S259 (2008)

    Article  PubMed  Google Scholar 

  6. Bader MS. Diabetic foot infection. Am. Fam. Phys. 78(1):71–79 (2008) (review)

    Google Scholar 

  7. E. Senneville, Infection and diabetic foot. Rev. Med. Interne 29(Suppl 2), S243–S248 (2008)

    Article  PubMed  Google Scholar 

  8. D.L. Eaton, B.E. Malloy, S.P. Tsai, Isolation, molecular cloning, partial characterization of a novel carboxypeptidase B from human plasma. J Biochem Chem 266, 21833–21838 (1991)

    CAS  Google Scholar 

  9. L. Bajzar, R. Manuel, M.E. Nesheim, Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor. J Biol Chem 270, 14477 (1995)

    Article  CAS  PubMed  Google Scholar 

  10. L. Bajzar, M.E. Nesheim, P.B. Tracy, The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI dependent. Blood 88, 2093–2100 (1996)

    CAS  PubMed  Google Scholar 

  11. C. Erem, A. Hacihasanoglu, S. Celik, E. Ovali, H.O. Ersoz, K. Ukinc, O. Deger, M. Telatar, Coagulation and fibrinolysis parameters in Type 2 diabetic patients with and without diabetic vascular complications. Med. Princ. Pract. 14, 22–30 (2005)

    Article  PubMed  Google Scholar 

  12. Y.T. Kruszynska, J.G. Yu, J.M. Olefsky, B.E. Sobel, Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes 49, 633–639 (2000)

    Article  CAS  PubMed  Google Scholar 

  13. A. Hamsten, U. de Faire, G. Walldius, G. Dahlén, A. Szamosi, C. Landou, M. Blombäck, B. Wiman, Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 8549, 3–9 (1987)

    Article  Google Scholar 

  14. Y. Hori, E.C. Gabazza, Y. Yano, A. Katsuki, K. Suzuki, Y. Adachi, Y. Sumida, Insulin resistance is associated with increased circulating levels of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients, J. Clin. Endocrinol. Metab. 87, 660–665 (2002)

    Article  CAS  Google Scholar 

  15. H. Aubert, C. Frere, M.F. Aillaud, P.E. Morange, I. Juhan-Vague, M.C. Alessi, Weak and nonindependent association between plasma TAFI antigen levels and the insulin resistance syndrome. J. Thromb. Haemost. 1, 791–797 (2003)

    Article  CAS  PubMed  Google Scholar 

  16. A.I. Adler, E.J. Boyko, J.H. Ahroni, D.G. Smith, Lower-extremity amputation in diabetes. the ındependent effects of peripheral vascular disease, sensory neuropathy, and foot ulcers. Diabetes Care 22, 1029–1035 (1999)

    Article  CAS  PubMed  Google Scholar 

  17. S.O. Oyibo, E.B. Jude, I. Tarawneh, H.C. Nquyen, L.B. Harkless et al., A comparison of two diabetic foot ulcer classification systems: the Wagner and the University of Texas wound classification systems. Diabetes Care 24, 84–88 (2001)

    Article  CAS  PubMed  Google Scholar 

  18. L. Prompers, M. Huijberts, J. Apelqvist, E. Jude et al., High prevalence of ischemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Diabetologia 50, 18–25 (2007)

    Article  CAS  PubMed  Google Scholar 

  19. K.C. Tan, W.S. Chow, V.H. Ai, Y.L. Siow et al., Hyperhomocysteinemia and Impaired vasomotor Function in Type 2 diabetes mellitus. Eur. J. Clin. Investig. 32, 328–334 (2002)

    Article  CAS  Google Scholar 

  20. M. Buysscheart, J. Jamart, A.S. Dramais, P. Wallemacq et al., Micro- and macrovascular complications and hyperhomocysteinemia in Type 1 diabetic patients. Diabetes Metab. 27, 655–659 (2001)

    Google Scholar 

  21. S.R. Kravitz, J. McGuire, S.D. Shanahan, Physical assessment of the diabetic foot. Adv. Skin Wound Care 16, 68–77 (2003)

    Article  PubMed  Google Scholar 

  22. W. Wang, M.B. Boffa, L. Bajzar et al., A study of the mechanism of inhibition of fibrinolysis by activated thrombinactivatable fibrinolysis inhibitor. J Biol Chem 273, 27176–27181 (1998)

    Article  CAS  PubMed  Google Scholar 

  23. Bentley J, Foster A. Multidisciplinary management of the diabetic foot ulcer. Br. J. Commun. Nurs. 12(12):S6, S8, S10 passim (2007)

  24. M.P. Khanolkar, S.C. Bain, J.W. Stephens, The diabetic foot. QJM 101(9), 685–695 (2008). Epub 2008 Mar 18

    Article  CAS  PubMed  Google Scholar 

  25. Al-Maskari F, El-Sadig M. Prevalence of risk factors for diabetic foot complications. BMC Fam. Pract. 8:59 (2007)

    Google Scholar 

  26. R. Gary Sibbald, K.Y. Woo, The biology of chronic foot ulcers in persons with diabetes. Diabetes Metab. Res. Rev. 24(Suppl 1), S25–S30 (2008)

    Article  PubMed  Google Scholar 

  27. P.C. Leung, Diabetic foot ulcers—a comprehensive review. Surgeon 5(4), 219–231 (2007). review

    Article  CAS  PubMed  Google Scholar 

  28. C.A. Andersen, T.S. Roukis, The diabetic foot. Surg. Clin. North Am. 87(5), 1149–1177 (2007)

    Article  PubMed  Google Scholar 

  29. H.M. Rathur, A.J.M. Boulton, The diabetic foot. Clin. Dermatol. 25, 109–120 (2007)

    Article  PubMed  Google Scholar 

  30. G.W. Gibbons, The diabetic foot, in Principles and Practice of Endocrinology and Metabolism, ed. by K.L.Becker, 3rd edn. (A Walter Kluwer Company, Philadelphia, 2001), pp. 1435–1438

  31. N. Papanas, E. Maltezos, Advances in treating the ischaemic diabetic foot. Curr. Vasc. Pharmacol. 6(1), 23–28 (2008)

    Article  CAS  PubMed  Google Scholar 

  32. A. Santamaria, A. Oliver, M. Borrell, J. Mateo, R. Belvis, J. Marti-Fabregas, R. Ortin, I. Tirado, J.C. Souto, J. Fontcuberta, Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels. Stroke 34(10), 2387–2391 (2003)

    Article  CAS  PubMed  Google Scholar 

  33. F.W. Leebeek, M.P. Goor, A.H. Guimaraes, G.J. Brouwers, M.P. Maat, D.W. Dippel, D.C. Rijken, High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke. J. Thromb. Haemost. 3(10), 2211–2218 (2005)

    Article  CAS  PubMed  Google Scholar 

  34. A. Santamaria, A. Martinez-Rubio, M. Borrell et al., Risk of acute coronary artery disease associated with functional thrombin activatable fibrinolysis inhibitor plasma level. Haematologica 89(7), 880–881 (2004)

    CAS  PubMed  Google Scholar 

  35. P. Lisowski, J. Malyszko, T. Hirnle et al., Thrombin activatable fibrinolysis inhibitor (TAFI) in stable angina pectoris patients undergoing coronary artery bypasses grafting (CABG). Rocz. Akad. Med. Bialymst. 50, 166–172 (2005)

    CAS  PubMed  Google Scholar 

  36. D. Tschoepe, The activated megakaryocyte-platelet-system in vascular disease: focus on diabetes. Semin. Thromb. Hemost. 21(2), 152–160 (1995)

    Article  CAS  PubMed  Google Scholar 

  37. J. Małyszko, J.S. Małyszko, T. Hryszko, M. Myśliwiec, Thrombin activatable fibrinolysis inhibitor (TAFI) and markers of endothelial cell injury in dialyzed patients with diabetic nephropathy. Thromb. Haemost. 91(3), 480–486 (2004)

    PubMed  Google Scholar 

  38. Y. Yano, N. Kitagawa, E.C. Gabazza, K. Morioka, H. Urakawa, T. Tanaka, A. Katsuki, R. Araki-Sasaki, Y. Hori, K. Nakatani, O. Taguchi, Y. Sumida, Y. Adachi, Increased plasma thrombin-activatable fibrinolysis inhibitor levels in normotensive type 2 diabetic patients with microalbuminuria. J. Clin. Endocrinol. Metab. 88(2), 736–741 (2003)

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology and Metabolism Disease, Ege University Medical School, Bornova, 35100, Izmir, Turkey

    M. Erdogan, S. Cetinkalp, A. G. Ozgen, F. Saygili & C. Yilmaz

  2. Department of Internal Medicine, Adana Numune Training and Research Hospital, Adana, Turkey

    S. Solmaz & A. Canataroglu

  3. Department of Endocrinology and Metabolism, Adana Numune Training and Research Hospital, Adana, Turkey

    M. Kulaksızoglu

Authors
  1. M. Erdogan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Solmaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Canataroglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Kulaksızoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Cetinkalp
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. G. Ozgen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. F. Saygili
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C. Yilmaz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Erdogan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Erdogan, M., Solmaz, S., Canataroglu, A. et al. Plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in diabetic foot ulcers. Endocr 37, 449–454 (2010). https://doi.org/10.1007/s12020-010-9329-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-010-9329-1

Keywords

Search

Navigation